isospaglumic acid has been researched along with Canavan Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Mattos Dutra, A; Dutra-Filho, CS; Henn, NT; Pederzolli, CD; Rockenbach, FJ; Romagna, EC; Sgaravatti, AM; Wajner, M; Wannmacher, CM; Wyse, AT; Zanin, FR | 1 |
| Baslow, MH; Guilfoyle, DN | 1 |
| Attwell, D; Hamilton, NB; Káradóttir, R; Kolodziejczyk, K; Wade, A | 1 |
| Barritault, J; Boespflug-Tanguy, O; Boildieu, N; Eymard-Pierre, E; Mochel, F; Sarret, C; Schiffmann, R; Seguin, F | 1 |
| Gradowska, W; Krawczyk, H | 1 |
| Campbell, GA; Ezell, EL; Matalon, R; Michals-Matalon, K; Quast, MJ; Rady, PL; Rassin, DK; Surendran, S; Szucs, S; Tyring, SK; Wei, J | 1 |
| Moffett, JR; Namboodiri, AM | 1 |
| Matalon, R; Michals-Matalon, K; Surendran, S; Tyring, SK | 1 |
| Assadi, M; Bilaniuk, L; Francis, J; Freese, A; Haselgrove, J; Hurh, P; Janson, CG; Leone, P; McPhee, SW; Shera, D; Wang, DJ | 1 |
| Burlina, AB; Burlina, AP; Corazza, A; Erhard, P; Ferrari, V; Künnecke, B; Seelig, J | 1 |
| Burlina, AB; Burlina, AP; Ferrari, V; Leon, A; Mazza, MR; Skaper, SD | 1 |
| Bennett, MJ; Burlina, AB; Burlina, AP; Dionisi-Vici, C; Divry, P; Ferrari, V; Gradowska, W; Jakobs, C; Sewell, AC | 1 |
2 review(s) available for isospaglumic acid and Canavan Disease
| Article | Year |
|---|---|
Preface: a brief review of N-acetylaspartate.
Topics: Animals; Aspartic Acid; Canavan Disease; Dipeptides; Energy Metabolism; Humans; Magnetic Resonance Spectroscopy; Myelin Sheath; Neurons; Osmolar Concentration | 2006 |
Canavan disease: studies on the knockout mouse.
Topics: Amidohydrolases; Animals; Canavan Disease; Dipeptides; gamma-Aminobutyric Acid; Gene Targeting; Genetic Therapy; Glutamic Acid; Humans; Mice; Mice, Knockout; Phenotype; Stem Cell Transplantation | 2006 |
10 other study(ies) available for isospaglumic acid and Canavan Disease
| Article | Year |
|---|---|
Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats.
Topics: Animals; Antioxidants; Aspartic Acid; Brain Damage, Chronic; Canavan Disease; Catalase; Cerebral Cortex; Dipeptides; Disease Models, Animal; Glucosephosphate Dehydrogenase; Glutathione Peroxidase; Injections, Intraventricular; Lipid Peroxidation; Male; Neuropeptides; Neurotoxins; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Wistar | 2009 |
Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
Topics: Amidohydrolases; Animals; Aspartic Acid; Astrocytes; Brain; Canavan Disease; Dipeptides; Disease Models, Animal; Extracellular Fluid; Humans; Myelin Sheath | 2009 |
The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes.
Topics: Action Potentials; Animals; Aspartic Acid; Calcium; Canavan Disease; Cerebellum; Dipeptides; Evoked Potentials; Glutamic Acid; Hydrolysis; Oligodendroglia; Patch-Clamp Techniques; Pelizaeus-Merzbacher Disease; Rats; Receptors, N-Methyl-D-Aspartate; Tissue Culture Techniques | 2009 |
Elevated CSF N-acetylaspartylglutamate suggests specific molecular diagnostic abnormalities in patients with white matter diseases.
Topics: Adolescent; Adult; Biomarkers; Canavan Disease; Child; Child, Preschool; Dipeptides; Female; Gene Duplication; Humans; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Myelin Proteolipid Protein; Organic Anion Transporters; Pelizaeus-Merzbacher Disease; Point Mutation; Sensitivity and Specificity; Symporters | 2010 |
Characterisation of the 1H and 13C NMR spectra of N-acetylaspartylglutamate and its detection in urine from patients with Canavan disease.
Topics: Canavan Disease; Child; Dipeptides; Humans; Hydrogen-Ion Concentration; Indicators and Reagents; Magnetic Resonance Spectroscopy; Protons | 2003 |
Expression of glutamate transporter, GABRA6, serine proteinase inhibitor 2 and low levels of glutamate and GABA in the brain of knock-out mouse for Canavan disease.
Topics: Amino Acid Transport System X-AG; Analysis of Variance; Animals; Azo Compounds; Brain Chemistry; Canavan Disease; Creatine; Dipeptides; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; In Vitro Techniques; Insect Proteins; Magnetic Resonance Spectroscopy; Mice; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Receptors, GABA-A; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, Protein | 2003 |
Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI.
Topics: Age Factors; Aspartic Acid; Atrophy; Brain; Canavan Disease; Case-Control Studies; Child, Preschool; Confidence Intervals; Diffusion Magnetic Resonance Imaging; Dipeptides; Female; Humans; Infant; Magnetic Resonance Spectroscopy; Male; Protons; Reference Values | 2006 |
Detection of increased urinary N-acetylaspartylglutamate in Canavan disease.
Topics: Canavan Disease; Child; Child, Preschool; Dipeptides; Female; Humans; Male | 1994 |
N-acetylaspartylglutamate selectively inhibits neuronal responses to N-methyl-D-aspartic acid in vitro.
Topics: Animals; Aspartic Acid; Canavan Disease; Cell Survival; Cells, Cultured; Cerebellum; Culture Media; Dipeptides; Kainic Acid; Mice; Mice, Inbred BALB C; N-Methylaspartate; Neurons | 1994 |
N-acetylaspartylglutamate in Canavan disease: an adverse effector?
Topics: Adolescent; Canavan Disease; Child; Child, Preschool; Dipeptides; Electrophoresis, Capillary; Humans; Infant; Infant, Newborn; Neuropeptides | 1999 |